Robecosam AG Has $19.93 Million Holdings in Boston Scientific Co. (BSX)

Robecosam AG raised its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 1.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 519,708 shares of the medical equipment provider’s stock after buying an additional 9,374 shares during the period. Robecosam AG’s holdings in Boston Scientific were worth $19,926,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of BSX. FMR LLC boosted its position in Boston Scientific by 10.4% during the second quarter. FMR LLC now owns 156,622,452 shares of the medical equipment provider’s stock valued at $5,121,554,000 after buying an additional 14,711,069 shares during the period. Morgan Stanley boosted its holdings in shares of Boston Scientific by 114.6% during the second quarter. Morgan Stanley now owns 7,517,384 shares of the medical equipment provider’s stock worth $245,818,000 after purchasing an additional 4,013,765 shares during the period. Epoch Investment Partners Inc. purchased a new stake in shares of Boston Scientific during the second quarter worth about $116,062,000. BlackRock Inc. boosted its holdings in shares of Boston Scientific by 2.9% during the second quarter. BlackRock Inc. now owns 109,355,395 shares of the medical equipment provider’s stock worth $3,575,920,000 after purchasing an additional 3,062,924 shares during the period. Finally, Massachusetts Financial Services Co. MA purchased a new stake in shares of Boston Scientific during the third quarter worth about $115,618,000. Institutional investors and hedge funds own 91.00% of the company’s stock.

In other Boston Scientific news, SVP John Bradley Sorenson sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, September 10th. The shares were sold at an average price of $35.86, for a total transaction of $358,600.00. Following the completion of the transaction, the senior vice president now owns 44,636 shares of the company’s stock, valued at $1,600,646.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP David A. Pierce sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 4th. The shares were sold at an average price of $36.02, for a total transaction of $180,100.00. The disclosure for this sale can be found here. Insiders sold 290,834 shares of company stock valued at $10,870,168 over the last 90 days. 0.73% of the stock is currently owned by company insiders.

BSX has been the subject of a number of analyst reports. Morgan Stanley increased their target price on shares of Boston Scientific from $33.00 to $38.00 and gave the stock an “overweight” rating in a report on Thursday, July 26th. Argus increased their target price on shares of Boston Scientific from $41.00 to $43.00 and gave the stock a “buy” rating in a report on Friday, October 26th. Piper Jaffray Companies increased their target price on shares of Boston Scientific to $38.00 and gave the stock an “overweight” rating in a report on Thursday, July 26th. Jefferies Financial Group reiterated a “hold” rating and set a $34.00 target price on shares of Boston Scientific in a report on Thursday, July 26th. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $37.00 target price on shares of Boston Scientific in a report on Thursday, July 26th. One analyst has rated the stock with a sell rating, two have issued a hold rating, nineteen have assigned a buy rating and three have assigned a strong buy rating to the stock. Boston Scientific has an average rating of “Buy” and an average price target of $39.00.

Shares of BSX opened at $36.19 on Wednesday. The company has a quick ratio of 0.60, a current ratio of 0.83 and a debt-to-equity ratio of 0.62. Boston Scientific Co. has a one year low of $24.54 and a one year high of $39.44. The stock has a market capitalization of $49.55 billion, a price-to-earnings ratio of 28.72, a P/E/G ratio of 2.32 and a beta of 0.59.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, October 24th. The medical equipment provider reported $0.35 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.34 by $0.01. Boston Scientific had a net margin of 6.93% and a return on equity of 27.38%. The business had revenue of $2.39 billion during the quarter, compared to analyst estimates of $2.40 billion. During the same period last year, the business posted $0.31 earnings per share. Boston Scientific’s quarterly revenue was up 7.7% compared to the same quarter last year. Sell-side analysts predict that Boston Scientific Co. will post 1.39 EPS for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

Featured Story: What is the Ex-Dividend Date in Investing?

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply